-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Luye Pharmaceutical Group announced that its subsidiary Luye Pharmaceuticals (Switzerland) and Esteve Pharmaceuticals, SA (ESTEVE) have reached an agreement to grant the latter the exclusive right to commercialize the Mindo Day transdermal patch in Spain
.
It is understood that Liss’ Mindorit transdermal patch is an innovative drug delivery route developed by the transdermal drug delivery technology platform of Luye Pharma AG, a German subsidiary of Luye Pharma; it is currently the core product of the group in the field of central nervous system therapy
.
It is mainly used to treat mild and moderate dementia related to Alzheimer's disease
.
Since the end of the review on May 21, 2021, the product has been eligible for marketing authorization in multiple participating member states of the European Union
.
In addition, the marketing authorization in Spain has also been obtained recently
.
Industry analysts believe that the reason why Liss’ Mingdori transdermal patch can be approved for marketing in many overseas countries so quickly is mainly because it has obvious advantages in treatment
.
Specifically, its innovation in the route of administration, twice a week through the skin, can improve the pain points of medication management for patients and their caregivers to a certain extent
.
Compared with the commercially available Liss' Mingdai transdermal patch, Liss's Mingda day transdermal patch has a lower frequency of use, which simplifies medication management while improving the patient's medication compliance; and oral administration Compared with the preparation, the drug is administered transdermally, which also provides good medication convenience for patients with dysphagia, and is expected to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting
.
At present, with the increasing number of patients, Alzheimer's disease has become a major public health challenge worldwide
.
The development of new drugs in the field of this disease has always been challenging.
Therefore, the industry expects that Liszamine, as the current first-line drug for the treatment of Alzheimer's disease-related dementia, will have considerable sales in the global market in the future
.
Statistics show that there are more than 50 million people with dementia in the world; and by 2050, this number is expected to increase to 152 million3
.
With the increasing number of patients, the market demand for Alzheimer's disease drugs will increase
.
In order to meet the needs of more patients, in fact, Luye Pharmaceuticals is accelerating the commercialization of Liss’ Mindo Day transdermal patches in various markets
.
In addition to granting Esteve Pharmaceuticals, SA (ESTEVE) the exclusive commercialization rights of Liss’ Mindo Day transdermal patch in Spain; in March this year, Luye Pharmaceuticals has already sold the product in four European countries.
Commercialization rights were granted to Italfarmaco Group
.
It believes that Italfarmaco, as a well-known pharmaceutical company with extensive experience in the field of central nervous system therapy and a strong commercial operation system, will expand the availability of Liss’ Mindoday patch to meet the unmet needs of patients in the region
.
In addition, not only in the European market, Liss’s Mindori transdermal patch is also about to start phase III clinical trials in Japan.
At present, the company has reached an agreement with Towa Pharmaceuticals on the development and commercialization rights of the product in the Japanese market; at the same time, Liss' Mingdo Day transdermal patch has also entered the clinical stage in China
.
In addition to the above countries, Luye Pharma is preparing to register the product in other countries and regions
.
.
It is understood that Liss’ Mindorit transdermal patch is an innovative drug delivery route developed by the transdermal drug delivery technology platform of Luye Pharma AG, a German subsidiary of Luye Pharma; it is currently the core product of the group in the field of central nervous system therapy
.
It is mainly used to treat mild and moderate dementia related to Alzheimer's disease
.
Since the end of the review on May 21, 2021, the product has been eligible for marketing authorization in multiple participating member states of the European Union
.
In addition, the marketing authorization in Spain has also been obtained recently
.
Industry analysts believe that the reason why Liss’ Mingdori transdermal patch can be approved for marketing in many overseas countries so quickly is mainly because it has obvious advantages in treatment
.
Specifically, its innovation in the route of administration, twice a week through the skin, can improve the pain points of medication management for patients and their caregivers to a certain extent
.
Compared with the commercially available Liss' Mingdai transdermal patch, Liss's Mingda day transdermal patch has a lower frequency of use, which simplifies medication management while improving the patient's medication compliance; and oral administration Compared with the preparation, the drug is administered transdermally, which also provides good medication convenience for patients with dysphagia, and is expected to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting
.
At present, with the increasing number of patients, Alzheimer's disease has become a major public health challenge worldwide
.
The development of new drugs in the field of this disease has always been challenging.
Therefore, the industry expects that Liszamine, as the current first-line drug for the treatment of Alzheimer's disease-related dementia, will have considerable sales in the global market in the future
.
Statistics show that there are more than 50 million people with dementia in the world; and by 2050, this number is expected to increase to 152 million3
.
With the increasing number of patients, the market demand for Alzheimer's disease drugs will increase
.
In order to meet the needs of more patients, in fact, Luye Pharmaceuticals is accelerating the commercialization of Liss’ Mindo Day transdermal patches in various markets
.
In addition to granting Esteve Pharmaceuticals, SA (ESTEVE) the exclusive commercialization rights of Liss’ Mindo Day transdermal patch in Spain; in March this year, Luye Pharmaceuticals has already sold the product in four European countries.
Commercialization rights were granted to Italfarmaco Group
.
It believes that Italfarmaco, as a well-known pharmaceutical company with extensive experience in the field of central nervous system therapy and a strong commercial operation system, will expand the availability of Liss’ Mindoday patch to meet the unmet needs of patients in the region
.
In addition, not only in the European market, Liss’s Mindori transdermal patch is also about to start phase III clinical trials in Japan.
At present, the company has reached an agreement with Towa Pharmaceuticals on the development and commercialization rights of the product in the Japanese market; at the same time, Liss' Mingdo Day transdermal patch has also entered the clinical stage in China
.
In addition to the above countries, Luye Pharma is preparing to register the product in other countries and regions
.
